NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of ...

EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs The results of the analytical ...

Timely results support recently proposed federal legislation which seeks to fund guaranteed fire fighter access to early detection tests such as EsoGuard NEW YORK, Sept. 6, 2023 /PRNewswire/ -- Lucid ...

NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its ...

First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida "This expansion into mobile testing is ...

Lucid Diagnostics' (NASDAQ:LUCD) EsoGuard test could get Medicare coverage soon, according to recent commentary from BTIG analysts. Analysts at BTIG said that during a day of investor meetings with ...

CEO Lishan Aklog highlighted the strong consensus from the recent MolDX Contract Advisory Committee (CAC) meeting, describing it as "the most significant event" and reinforcing confidence in being "in ...

BioTech Breakthrough’s Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry “We believe EsoGuard, the first and only commercially available diagnostic ...